Guggenheim Capital LLC trimmed its stake in argenx SE (NASDAQ:ARGX - Free Report) by 16.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,328 shares of the company's stock after selling 679 shares during the period. Guggenheim Capital LLC's holdings in argenx were worth $2,047,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Sanctuary Advisors LLC lifted its position in argenx by 17.5% in the third quarter. Sanctuary Advisors LLC now owns 2,064 shares of the company's stock worth $1,119,000 after purchasing an additional 308 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of argenx in the 3rd quarter valued at $652,000. Lord Abbett & CO. LLC bought a new position in shares of argenx during the 3rd quarter worth about $88,339,000. GAMMA Investing LLC boosted its position in shares of argenx by 44.8% during the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company's stock valued at $155,000 after acquiring an additional 78 shares in the last quarter. Finally, Central Pacific Bank Trust Division acquired a new stake in shares of argenx during the 4th quarter valued at about $615,000. Institutional investors own 60.32% of the company's stock.
argenx Price Performance
ARGX stock traded down $5.22 during mid-day trading on Wednesday, reaching $594.65. The company had a trading volume of 244,073 shares, compared to its average volume of 308,499. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The company has a market capitalization of $36.31 billion, a price-to-earnings ratio of -675.74 and a beta of 0.60. The stock has a 50 day simple moving average of $600.43 and a two-hundred day simple moving average of $606.78.
argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, equities analysts predict that argenx SE will post 3.13 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have commented on ARGX shares. Guggenheim lifted their price objective on argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a report on Monday, March 10th. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Wedbush reissued an "outperform" rating and set a $715.00 price target on shares of argenx in a research note on Friday, April 11th. HC Wainwright reaffirmed a "buy" rating and set a $720.00 price objective on shares of argenx in a report on Tuesday, April 8th. Finally, JMP Securities lifted their target price on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $699.28.
Get Our Latest Stock Analysis on argenx
About argenx
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Further Reading
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
